Lipophilic, acid-stable, adenosine deaminase-activated anti-HIV prodrugs for central nervous system delivery. 3. 6-amino prodrugs of 2′-β-fluoro-2′,3′-dideoxyinosine

Journal of Medicinal Chemistry

Volumn 39, Issue 8, 1996, Pages 1619-1625

  Driscoll, John S ^a   Siddiqui, Maqbool A ^a   Ford Jr , Harry ^a   Kelley, James A ^a   Roth, Jeri S ^a   Mitsuya, Hiroaki ^b   Tanaka, Masatoshi ^b   Marquez, Victor E ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXY 2' FLUORO 6 N,N DIMETHYLADENOSINE; 2',3' DIDEOXY 2' FLUOROINOSINE; ADENOSINE DEAMINASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PRODRUG; PURINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CATALYSIS; CELL PROTECTION; DRUG HYDROLYSIS; DRUG STABILITY; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOPHILICITY;

ADENOSINE DEAMINASE; ANTIVIRAL AGENTS; BRAIN; DIDANOSINE; HIV; HUMANS; HYDROLYSIS; PRODRUGS; SOLUBILITY;

EID: 0029975891     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9509197     Document Type: Article

References (41)

1. 50, compound concentration inhibiting HIV cytopathogenic effects by 50%; NCI, National Cancer Institute; P, octanol/pH 7.4 buffer partition coefficient; PHA-PBM, phytohemagglutinin-stimulated peripheral blood mononuclear cells; PNP, purine nucleoside phosphorylase.
2. (a) Geleziunas, R.; Schipper, H. M.; Wainberg, M. A. Pathogenesis and Therapy of HIV-1 Infection of the Central Nervous System. AIDS 1992, 6, 1411-1426.
3. (b) Atwood, W. J.; Berger, J. R.; Kaderman, R.; Tornatore, C. S.; Major, E. O. Human Immunodeficiency Virus Type 1 Infection of the Brain. Clin. Microbiol. Rev. 1993, 6, 339-366.
4. De Clercq, E. Antiviral Therapy for Human Immunodeficiency Virus Infections. Clin. Microbiol. Rev. 1995, 8, 200-239.
5. (a) Yarchoan, Y.; Mitsuya, H.; Broder, S. Challenges in the therapy of HIV Infection. Immunol. Today 1993, 14, 303-309.
6. (b) Shanmuganathan, K.; Koudriakova, T.; Nampalli, S.; Du, J.; Gallo, J. M.; Schinazi, R. F.; Chu, C. K Enhanced Brain Delivery of an Anti-HIV Nucleoside 2′-F-ara-ddI by Xanthine Oxidase Mediated Biotransformation. J. Med. Chem. 1994, 37, 821-827.
7. (a) Ford, H.; Siddiqui, M. A.; Driscoll, J. S.; Marquez, V. E.; Kelley, J. A.; Mitsuya, H.; Shirasaka, T. Lipophilic, Acid-Stable Adenosine Deaminase-Activated Anti-HIV Prodrugs for Central Nervous System Delivery, 2. 6-Halo and 6-Alkoxy Prodrugs of 2′-β-Fluoro-2′,3′-dideoxyinosine. J. Med. Chem. 1995, 38, 1189-1195.
8. (b) Barchi, J. J.; Marquez, V E.; Driscoll, J. S.; Ford, H.; Mitsuya, H.; Shirasaka, T.; Aoki, S.; Kelley, J. A. Potential Anti-AIDS Drugs. Lipophilic, Adenosine Deaminase-Activated Prodrugs. J. Med. Chem. 1991, 34, 1647-1655.
9. Marquez, V. E.; Tseng, C. K-H.; Mitsuya, H.; Aoki, S.; Kelley, J. A.; Ford, H.; Roth. J. S.; Broder, S.; Johns, D. G.; Driscoll, J. S. Acid-Stable 2′-Fluoro Purine Dideoxynucleosides as Active Agents Against HIV. J. Med. Chem. 1990, 33, 978-985.
10. (a) Marquez, V. E.; Tseng, C. K.-H.; Kelley, J. A.; Mitsuya, H.; Broder, S.; Roth, J. S.; Driscoll, J. S. 2′,3′-Dideoxy-2′-Fluoro-Ara-A. An Acid-Stable Purine Nucleoside Active Against Human Immunodeficiency Virus (HIV). Biochem. Pharmacol. 1987, 36, 2719-2722.
11. (b) Herdewijn, P.; Pauwels, R.; Baba, M.; Balzarini, J.; De Clercq, E. Synthesis and Anti-HIV Activity of Various 2′-and 3′-Substituted 2′,3′-Dideoxyadenosines: A Structure-Activity Analysis. J. Med. Chem. 1987, 30, 2131-2137.
12. Driscoll, J. S. The Chemistry and Biology of Fluorodideoxyadenosine: A New Anti-AIDS Clinical Drug Candidate. In Proceedings of the International Symposium on Pharmaceutical Sciences Commemorating the 80th Anniversary of Modern Pharmaceutical Education in Korea; Chung, Won-Keun, Lee, Sang Sup, Kim, Nak Doo Kim, et al., Eds.; Pharm. Soc. Korea: Seoul, 1995; pp 88-96.
13. Masood, R.; Ahluwalia, G. S.; Cooney, D. A.; Fridland, A.; Marquez, V. E.; Driscoll, J. S.; Hao, Z.; Mitsuya, H.; Perno, C.-F.; Broder, S.; Johns, D. G. 2′-Fluoro-2′,3′-Dideoxyarabinosyladenine: A Metabolically Stable Analogue of the Antiretroviral Agent 2′,3′-Dideoxyinosine. Mol. Pharmacol. 1990, 37, 590-596.
14. (a) Wysocki, R. J.; Siddiqui, M. A.; Barchi, J. J.; Driscoll, J. S.; Marquez, V. E. A More Expedient Approach to the Synthesis of the Anti-HIV-Active 2,3-Dideoxy-2-fluoro-β-D-thero-pentofuranosyl Nucleosides. Synthesis 1991, 1005-1008.
15. (b) Siddiqui, M. A.; Marquez, V. E.; Driscoll, J. S.; Barchi, J. J. A Diasteroselective Synthesis of (S,S)-α-Fluoro-2,2-Dimethyl-1,3-Dioxolane-4-Propanoic Acid Methyl Ester, a Key Intermediate for the Preparation of Anti-HIV Effective Fluorodideoxynucleosides. Tetrahedron Lett. 1994, 35, 3263-3266.
16. Chassy, B. M.; Suhadolnik, R. J. Adenosine Aminohydrolase. Binding and Hydrolysis of 2- and 6-Substituted Purine Ribonucleosides and 9-Substituted Adenine Nucleosides. J. Biol. Chem. 1967, 242, 3655-3658.
17. Baer, H. P.; Drummond, G. I.; Gillis, J. Studies on the Specificity and Mechanism of Action of Adenosine Deaminase. Arch. Biochem. Biophys. 1968, 123, 172-178
18. (a) Johnson, J. A.; Thomas, H. J.; Schaeffer, H. J. Synthesis of Potential Anticancer Agents. XIII. Ribosides of 6-Substituted Purines. J. Am. Chem. Soc. 1958, 79, 699-702.
19. (b) Wolfenden, R. Enzymatic Hydrolysis of 6-Substituents on Purine Ribosides. J. Am. Chem. Soc. 1966, 88, 3157-3158.
20. Ford, H.; Merski, C. L.; Kelley, J. A. A Rapid Microscale Method for the Determination of Partition Coefficients by HPLC. J. Liquid Chromatogr. 1991, 14, 3365-3386.
21. Craig, P. N. Interdepencence Between Physical Parameters and Selection of Substitutent Groups for Correlation Studies. J. Med. Chem. 1971, 14, 680-684.
22. (a) York, J. L. Effect of the Structure of the Glycon on the Acid-Catalyzed Hydrolysis of Adenine Nucleosides. J. Org. Chem. 1981, 46, 2171-2173.
23. (b) Faulds, D.; Brogden, R. N. Didanosine. A Review of its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Potential in Human Immunodeficiency Virus Infection. Drugs 1992, 1, 94-116.
24. (a) Simon, L. N.; Bauer, R. J.; Tolman, R. L.; Robins, R. K. Calf Intestine Adenosine Deaminase. Substrate Specificity. Biochemistry 1970, 9, 573-577.
25. (b) Frederiksen, S. Specificity of Adenosine Deaminase Toward Adenosine and 2′-Deoxyadenosine Analogues. Arch. Biochem. Biophys. 1966, 113, 383-388.
26. (c) Corey, J. G.; Suhadolnik, R. J. Structural Requirements of Nucleosides for Binding by Adenosine Deaminase. Biochemistry 1966, 4, 1729-1732, 1733-1735.
27. (d) Wright, J. A.; Wilson, D. P.; Fox, J. J. Nucleosides. LXIV. Fluoro Sugar Analogs of Arabinosyl- and Xylosylcytosines. J. Med. Chem. 1970, 13, 269-272.
28. (e) Biron, K. K.; De Miranda, P.; Burnette, T. C.; Krenitsky, T. A. Selective Anabolism of 6-Methoxypurine Arabinoside in Varicella-Zoster Virus-Infected Cells. Antimicrob. Agents Chemother. 1991, 35, 2116-2120.
29. (f) Pauwels, R.; Baba, M.; Balzarini, J.; Herdewijn, P.; Desmyther, J.; Robins, M. J.; Zou, R.; Madej, D.; De Clercq, E. Investigations on the Anti-HIV Activity of 2′,3′-Dideoxyadenosine Analogues with Modifications in either the Pentose or Purine Moiety. Biochem. Pharmacol. 1988, 37, 1317-1325.
30. Gao, W.-Y.; Agbaria, R.; Driscoll, J. S.; Mitsuya. H. Divergent Anti-human Immunodeficiency Virus Activity and Anabolic Phosphorylation of 2′,3′-Dideoxymicleoside Analogs in Resting and Activated Human Cells. J. Biol. Chem. 1994, 269, 12633-12638.
31. Shirasaka, T.; Murakami, K.; Ford, H.; Kelley, J. A.; Yoshioka, H.; Kojima, E.; Aoki, S.; Broder, S.: Mitsuya, H. Lipophilic Halogenated Congeners of 2′,3′-Dideoxypurine Nucleosides Active Against Human Immunodeficiency Virus In Vitro. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 9426-9430.
32. Gulakowski, R. J.; McMahon, J. B.; Staley, P. G.; Moran, R. A.; Boyd, M. R. A Semiautomated Multiparameter Approach for Anti-HIV Drug Screening. J. Virolog. Meth. 1991, 33, 87-100.
33. Raiteri, R.; Marietti, G.; Scolfaro, C.; Sinicco, A. Adenosine deaminase and HIV Infection. Med. Sci. Res. 1989, 17, 187-188.
34. Casoli, C.; Lisa, A.; Magnani, G.; Starcich, R.; Fiaccadori, F.; Bertazzoni, U.; Zei, G. Prognostic Value of Adenosine Deaminase Compared to Other Markers for Progression to Acquired Immunodeficiency Syndrome Among Intravenous Drug Users. J. Med. Virol. 1995, 45, 203-210.
35. Anderson, B. D.; Galinsky, R. E.; Baker, D. C.; Chi, S.-C.; Hoesterey, B. L.; Morgan, M. E.; Murakami, K.; Mitsuya, H. Approaches Towards the Optimization of CNS Uptake of Anti-AIDS Agents. J. Control. Rel. 1992, 19, 219-230.
36. Shirasaka, T.; Watanabe, K.; Yoshioka, H.; Kojima, E.; Aoki, S.; Murakami, K.; Mitsuya, H. Lipophilic 6-Halo-2′,3′-dideoxypurine Nucleosides: Potential Antiretroviral Agents Targeting HIV-Associated Neurologic Disorders. In Advances in Molecular Biology and Targeted Treatment for AIDS; Kumar, A., Ed.; Plenum Press: New York, 1991; pp 323-333.
37. Morgan, M. E.; Chi, S.-C.; Murakami, K.; Mitsuya, H.; Anderson, B. D. Central Nervous System Targeting of 2′,3′-Dideoxyinosine via Adenosine Deaminase-Activated 6-Halo-Dideoxypurine Prodrugs. Antimicrob. Agents Chemother. 1992, 36, 2156-2165.
38. Doshi, K. J.; Boudinot, F. D.; Gallo, J. M.; Schinazi, R. F.; Chu, C. K. Brain Targeting of Anti-HIV Nucleosides: In Vitro and In Vivo Evaluation of 6-Chloro-2′,3′-dideoxypurine, a Lipophilic prodrug of 2′,3′-Dideoxyinosine. Antiviral Agents Chemother. 1994, 5, 304-311.
39. Anderson, B. D.; Morgan, M. E.; Singhai, D. Enhanced Oral Bioavailability of ddI After Administration of 6-Cl-ddP, an Adenosine Deaminase-Activated Prodrug, to Chronically Catheterized Rats. Pharm. Res. 1995, 12, 1126-1133.
40. Musser, S. M.; Kelley, J. A. A Mechanism for Dehalogenation Reactions in Fast Atom Bombardment Mass Spectrometry. Org. Mass Spectrom. 1993, 28, 672-678.
41. Feenstra, R. W.; Stokkingreef, E. H. M.; Nivard, R. J. F.; Ottenheijm, H. C. J. An Efficient Synthesis of N-Hydroxy-α-amino Acids Derivatives of High Optical Purity. Tetrahedron Lett. 1987, 1215-1218.